Novel lipid-lowering therapies such as proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) can dramatically lower low-density lipoprotein (LDL) and lipoprotein(a) levels, but are not ...

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol. The new ...

Amgen Inc (AMGN) reports a 19% revenue increase, driven by strong product sales and strategic international expansions, ...

The long-running legal dispute between Amgen and Sanofi/Regeneron on two key patents covering the use of PCSK9 inhibitors to lower cholesterol has come to an end, with Sanofi emerging as the victor.

An article in Cell now describes a germline mutation in proprotein convertase subtilisin/kexin type 9 (PCSK9) that is associated with reduced survival in patients with breast cancer. Inhibition of ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

“This one is cool because the mechanism is pretty different from statins and PCSK9 inhibitors,” says Khera. “It can lower the LDL even if patients don’t have any LDL receptors. It has the ...

so they don’t have that same effect of causing liver damage. PCSK9 inhibitors are a new class of medications that may be available to patients to help reduce their cholesterol. By inhibiting a ...

Another, newer type of cholesterol drug is called PCSK9 inhibitors. These medications work differently by clearing cholesterol already stored in the body’s cells. While both types are effective ...